HopeStage
Back to all studies
TerminatedNCT01093963

Efficacy Study of Lisdexamfetamine to Treat Depression in bipolarity

Medication studyAges 18–55United States
The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 55 years.

Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateJanuary 2010
Recruitment status
Terminated
Enrollment listed in the registry
25
Sponsor
Lindner Center of HOPE
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States
Age range
From 18 Years to 55 Years
Official registry ID
NCT01093963
Official title
Show the full official title

Adjunctive Lisdexamfetamine in Bipolar Depression

Recruitment & locations

Terminated

Mason

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Lindner Center of HOPE.

Does this study involve medication?

Yes. The study involves medication, including Lisdexamfetamine and Placebo.

Who can participate?

Listed age limits: 18 years to 55 years.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies